Free tool
FAERS Monitor: Hetlioz Lq
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214517 or its brand name (Hetlioz Lq, Tasimelteon). Reports on generic versions are filed under their own applications.
Reports
5,893
Serious
601
10% of reports
Hospitalization
288
Death reported
166
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,652
- insomnia747
- product dose omission issue504
- middle insomnia424
- somnolence412
- headache387
- nightmare272
- fatigue225
- abnormal dreams224
- therapeutic product effect decreased199
- sleep disorder193
- inappropriate schedule of product administration185
- incorrect product administration duration165
- poor quality sleep159
- initial insomnia153
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 9 |
| 2015 | 577 |
| 2016 | 408 |
| 2017 | 308 |
| 2018 | 540 |
| 2019 | 776 |
| 2020 | 741 |
| 2021 | 731 |
| 2022 | 556 |
| 2023 | 562 |
| 2024 | 377 |
| 2025 | 177 |
| 2026 | 131 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,266 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| middle insomniaSignal | 424 | 82.9 | 75.6 | 33,482 |
| initial insomniaSignal | 153 | 54.0 | 46.1 | 7,793 |
| abnormal dreamsSignal | 224 | 29.2 | 25.7 | 6,027 |
| nightmareSignal | 272 | 28.3 | 25.2 | 7,084 |
| incorrect product administration durationSignal | 165 | 27.4 | 23.5 | 4,141 |
| poor quality sleepSignal | 159 | 26.5 | 22.8 | 3,859 |
| therapeutic product effect decreasedSignal | 199 | 15.9 | 13.9 | 2,762 |
| insomniaSignal | 747 | 10.0 | 9.4 | 6,128 |
| sleep disorderSignal | 193 | 9.8 | 8.5 | 1,514 |
| somnolenceSignal | 412 | 7.3 | 6.7 | 2,257 |
| product dose omission issueSignal | 504 | 6.1 | 5.6 | 2,183 |
| drug ineffectiveSignal | 1,652 | 4.5 | 4.3 | 4,752 |
| inappropriate schedule of product administrationSignal | 185 | 3.7 | 3.2 | 359 |
| headacheSignal | 387 | 2.2 | 2.0 | 261 |
| fatigue | 225 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.